NUS Ebit vs Research Development Analysis

NUS Stock

USD 7.22 0.08 1.10%

Nu Skin financial indicator trend analysis is infinitely more than just investigating Nu Skin Enterprises recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nu Skin Enterprises is a good investment. Please check the relationship between Nu Skin Ebit and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nu Skin Enterprises. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nu Skin Enterprises Ebit account and Research Development. At this time, the significance of the direction appears to have no relationship.

The correlation between Nu Skin's Ebit and Research Development is 0.04. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Nu Skin Enterprises, assuming nothing else is changed. The correlation between historical values of Nu Skin's Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Nu Skin Enterprises are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Nu Skin's Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ebit

Research Development

Most indicators from Nu Skin's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nu Skin Enterprises current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nu Skin Enterprises. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

At this time, Nu Skin's Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.37 in 2024, despite the fact that Tax Provision is likely to grow to (16.1 M).

	2021	2022	2023	2024 (projected)
Gross Profit	2.0B	1.6B	1.4B	1.4B
Total Revenue	2.7B	2.2B	2.0B	1.8B

Gross Profit Total Revenue

Nu Skin fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Short Term Debt	Property Plant And Equipment Gross	Good Will	Common Stock Total Equity	Intangible Assets
Total Assets		0.61	0.77	0.96	0.94	0.22	0.96	0.76	0.72	0.95	0.49	0.73	0.62	-0.87	0.61	0.93	0.5	-0.76	0.97	0.91	0.56	0.16	0.57	0.56	0.07	-0.19
Other Current Liab	0.61		0.94	0.59	0.43	-0.46	0.4	0.8	0.88	0.35	0.37	0.88	0.45	-0.28	-0.01	0.61	0.68	-0.16	0.6	0.86	-0.04	0.15	0.16	-0.1	-0.22	-0.19
Total Current Liabilities	0.77	0.94		0.73	0.62	-0.29	0.6	0.89	0.91	0.55	0.33	0.91	0.52	-0.49	0.17	0.78	0.65	-0.37	0.77	0.95	0.15	0.32	0.27	0.11	-0.18	-0.2
Total Stockholder Equity	0.96	0.59	0.73		0.89	0.15	0.91	0.66	0.64	0.9	0.55	0.65	0.54	-0.8	0.51	0.91	0.65	-0.64	0.87	0.89	0.44	0.11	0.5	0.46	0.0	-0.25
Property Plant And Equipment Net	0.94	0.43	0.62	0.89		0.36	0.96	0.57	0.55	0.96	0.4	0.55	0.48	-0.83	0.65	0.89	0.3	-0.8	0.92	0.77	0.63	0.23	0.58	0.64	0.03	-0.24
Net Debt	0.22	-0.46	-0.29	0.15	0.36		0.38	-0.18	-0.34	0.46	-0.05	-0.34	0.43	-0.59	0.85	0.18	-0.36	-0.72	0.26	-0.13	0.88	-0.01	0.75	0.71	0.66	0.14
Retained Earnings	0.96	0.4	0.6	0.91	0.96	0.38		0.61	0.57	0.99	0.51	0.57	0.5	-0.91	0.69	0.88	0.31	-0.85	0.94	0.77	0.65	0.18	0.57	0.64	0.11	-0.25
Accounts Payable	0.76	0.8	0.89	0.66	0.57	-0.18	0.61		0.88	0.58	0.2	0.88	0.62	-0.56	0.3	0.66	0.56	-0.44	0.79	0.88	0.25	0.07	0.28	0.27	-0.08	-0.02
Cash	0.72	0.88	0.91	0.64	0.55	-0.34	0.57	0.88		0.51	0.5	1.0	0.45	-0.49	0.19	0.6	0.51	-0.37	0.74	0.89	0.13	0.1	0.21	0.03	-0.24	-0.21
Non Current Assets Total	0.95	0.35	0.55	0.9	0.96	0.46	0.99	0.58	0.51		0.45	0.51	0.58	-0.92	0.75	0.85	0.3	-0.86	0.93	0.74	0.71	0.1	0.65	0.73	0.2	-0.13
Non Currrent Assets Other	0.49	0.37	0.33	0.55	0.4	-0.05	0.51	0.2	0.5	0.45		0.49	0.11	-0.48	0.26	0.39	0.26	-0.37	0.41	0.47	0.15	-0.14	0.2	-0.09	-0.13	-0.53
Cash And Short Term Investments	0.73	0.88	0.91	0.65	0.55	-0.34	0.57	0.88	1.0	0.51	0.49		0.46	-0.49	0.19	0.61	0.53	-0.36	0.74	0.89	0.13	0.09	0.21	0.03	-0.24	-0.2
Net Receivables	0.62	0.45	0.52	0.54	0.48	0.43	0.5	0.62	0.45	0.58	0.11	0.46		-0.67	0.71	0.48	0.38	-0.61	0.64	0.57	0.68	-0.21	0.83	0.54	0.58	0.34
Common Stock Shares Outstanding	-0.87	-0.28	-0.49	-0.8	-0.83	-0.59	-0.91	-0.56	-0.49	-0.92	-0.48	-0.49	-0.67		-0.88	-0.75	-0.22	0.95	-0.87	-0.66	-0.83	-0.08	-0.76	-0.65	-0.34	0.18
Non Current Liabilities Total	0.61	-0.01	0.17	0.51	0.65	0.85	0.69	0.3	0.19	0.75	0.26	0.19	0.71	-0.88		0.49	-0.09	-0.94	0.66	0.33	0.98	-0.06	0.88	0.75	0.54	0.03
Inventory	0.93	0.61	0.78	0.91	0.89	0.18	0.88	0.66	0.6	0.85	0.39	0.61	0.48	-0.75	0.49		0.51	-0.68	0.88	0.88	0.47	0.43	0.46	0.5	-0.03	-0.3
Other Current Assets	0.5	0.68	0.65	0.65	0.3	-0.36	0.31	0.56	0.51	0.3	0.26	0.53	0.38	-0.22	-0.09	0.51		0.03	0.35	0.69	-0.16	-0.06	0.14	-0.16	-0.08	-0.12
Other Stockholder Equity	-0.76	-0.16	-0.37	-0.64	-0.8	-0.72	-0.85	-0.44	-0.37	-0.86	-0.37	-0.36	-0.61	0.95	-0.94	-0.68	0.03		-0.81	-0.51	-0.93	-0.18	-0.79	-0.7	-0.36	0.18
Total Liab	0.97	0.6	0.77	0.87	0.92	0.26	0.94	0.79	0.74	0.93	0.41	0.74	0.64	-0.87	0.66	0.88	0.35	-0.81		0.87	0.63	0.19	0.59	0.61	0.12	-0.12
Total Current Assets	0.91	0.86	0.95	0.89	0.77	-0.13	0.77	0.88	0.89	0.74	0.47	0.89	0.57	-0.66	0.33	0.88	0.69	-0.51	0.87		0.28	0.21	0.38	0.26	-0.11	-0.23
Short Long Term Debt Total	0.56	-0.04	0.15	0.44	0.63	0.88	0.65	0.25	0.13	0.71	0.15	0.13	0.68	-0.83	0.98	0.47	-0.16	-0.93	0.63	0.28		0.06	0.89	0.76	0.57	0.06
Short Term Debt	0.16	0.15	0.32	0.11	0.23	-0.01	0.18	0.07	0.1	0.1	-0.14	0.09	-0.21	-0.08	-0.06	0.43	-0.06	-0.18	0.19	0.21	0.06		-0.07	0.06	-0.22	-0.28
Property Plant And Equipment Gross	0.57	0.16	0.27	0.5	0.58	0.75	0.57	0.28	0.21	0.65	0.2	0.21	0.83	-0.76	0.88	0.46	0.14	-0.79	0.59	0.38	0.89	-0.07		0.57	0.7	0.15
Good Will	0.56	-0.1	0.11	0.46	0.64	0.71	0.64	0.27	0.03	0.73	-0.09	0.03	0.54	-0.65	0.75	0.5	-0.16	-0.7	0.61	0.26	0.76	0.06	0.57		0.41	0.34
Common Stock Total Equity	0.07	-0.22	-0.18	0.0	0.03	0.66	0.11	-0.08	-0.24	0.2	-0.13	-0.24	0.58	-0.34	0.54	-0.03	-0.08	-0.36	0.12	-0.11	0.57	-0.22	0.7	0.41		0.55
Intangible Assets	-0.19	-0.19	-0.2	-0.25	-0.24	0.14	-0.25	-0.02	-0.21	-0.13	-0.53	-0.2	0.34	0.18	0.03	-0.3	-0.12	0.18	-0.12	-0.23	0.06	-0.28	0.15	0.34	0.55

Click cells to compare fundamentals

Nu Skin Account Relationship Matchups

Nu Skin fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	2.0B	1.9B	1.8B	1.8B	1.2B
Other Current Liab	270.1M	307.7M	274.5M	202.0M	194.8M	206.6M
Total Current Liabilities	356.8M	542.9M	529.7M	359.2M	328.9M	305.0M
Total Stockholder Equity	875.3M	894.3M	912.8M	897.3M	822.0M	572.2M
Property Plant And Equipment Net	597.9M	653.5M	574.6M	543.5M	523.1M	263.7M
Net Debt	132.0M	97.7M	125.4M	214.3M	351.3M	368.8M
Retained Earnings	1.7B	1.8B	1.9B	1.9B	1.9B	1.0B
Accounts Payable	39.0M	66.2M	50.0M	54.0M	43.5M	34.4M
Cash	335.6M	402.7M	339.6M	264.7M	256.1M	248.8M
Non Current Assets Total	1.0B	1.1B	1.0B	1.1B	1.1B	607.3M
Non Currrent Assets Other	154.0M	50.6M	113.1M	115.2M	99.8M	104.3M
Cash And Short Term Investments	344.0M	423.9M	354.8M	278.5M	267.8M	256.4M
Net Receivables	50.4M	63.4M	41.3M	47.4M	72.9M	76.5M
Common Stock Shares Outstanding	55.9M	52.8M	51.4M	50.5M	49.9M	54.3M
Liabilities And Stockholders Equity	1.8B	2.0B	1.9B	1.8B	1.8B	1.2B
Non Current Liabilities Total	537.0M	519.9M	464.0M	564.4M	655.6M	688.4M
Inventory	275.9M	314.4M	399.9M	346.2M	280.0M	187.9M
Other Current Assets	69.9M	101.6M	76.9M	87.8M	81.2M	69.5M
Other Stockholder Equity	(767.3M)	(881.8M)	(925.2M)	(955.8M)	(948.6M)	(901.2M)
Total Liab	893.7M	1.1B	993.7M	923.7M	984.5M	586.6M
Total Current Assets	740.2M	903.2M	873.0M	759.9M	701.9M	551.5M
Short Long Term Debt Total	467.7M	500.4M	465.0M	479.0M	607.3M	637.7M
Short Term Debt	27.5M	75.0M	140.9M	54.4M	48.9M	54.5M
Property Plant And Equipment Gross	597.9M	653.5M	453.7M	444.8M	897.6M	942.5M
Accumulated Other Comprehensive Income	(85.3M)	(64.8M)	(73.9M)	(86.5M)	(100.0M)	(105.0M)
Intangible Assets	80.3M	89.5M	77.0M	66.7M	105.3M	84.0M
Other Liab	96.8M	102.3M	106.5M	98.3M	113.0M	72.4M
Other Assets	154.0M	293.2M	175.5M	244.4M	281.1M	152.1M
Long Term Debt	334.5M	305.4M	268.8M	377.5M	478.0M	501.9M
Property Plant Equipment	453.6M	468.2M	453.7M	444.8M	511.5M	275.1M
Current Deferred Revenue	20.2M	35.1M	33.1M	27.1M	20.4M	17.9M
Short Term Investments	8.4M	21.2M	15.2M	13.8M	11.8M	13.7M
Treasury Stock	(1.3B)	(1.3B)	(1.5B)	(1.5B)	(1.4B)	(1.3B)
Net Tangible Assets	875.3M	894.3M	912.8M	897.3M	1.0B	829.4M
Retained Earnings Total Equity	1.7B	1.8B	1.9B	1.9B	2.2B	1.6B
Long Term Debt Total	334.5M	313.1M	274.1M	389.6M	448.0M	321.7M
Capital Surpluse	557.5M	579.8M	601.7M	613.3M	705.3M	500.0M
Non Current Liabilities Other	105.7M	112.3M	88.8M	76.5M	9.0M	8.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NUS Stock Analysis

When running Nu Skin's price analysis, check to measure Nu Skin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Skin is operating at the current time. Most of Nu Skin's value examination focuses on studying past and present price action to predict the probability of Nu Skin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Skin's price. Additionally, you may evaluate how the addition of Nu Skin to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC